SynthesisScientific reports2025
Preoperative radiotherapy combined with surgery versus surgery alone for primary retroperitoneal sarcoma: a meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Radiotherapy for Soft Tissue Sarcomas in 2025: A Review.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The efficacy of preoperative radiotherapy combined with surgery (preRT + S) for primary retroperitoneal sarcoma (RPS) remains unclear. This study aimed to compare preRT + S with surgery alone (SA) in patients with RPS. Core databases were searched for directly comparative studies depending on preRT. Thirteen studies included 2,439 patients with SA and 1,453 with preRT + S. PreRT + S in all RPS patients led to significantly low local recurrence (LR) (hazard ratios [HR],0.575; p = 0.008) compared to SA. Among the liposarcoma patients, PreRT + S did not clearly affect LR or abdominal recurrence-free survival (ARFS). Excluding dedifferentiated liposarcoma (DDLPS), the patients underwent preRT + S significantly improved LR (HR,0.430; p = 0.002) and ARFS (HR,0.706; p = 0.045). In another subgroup analysis of patients with well-differentiated liposarcoma and grade 1-2 DDLPS, preRT + S significantly extended ARFS (HR,0.601; p = 0.014) compared to SA. There was no significant difference in overall survival (OS) (HR,0.904; p = 0.362 [RPS]; HR,0.724; p = 0.348 [WDLPS + G1-2DDLPS]) between preRT + S and SA in all comparisons. PreRT + S group demonstrated higher incidence of total (odds ratio [OR],1.580; p = 0.007) and severe (OR,3.680; p = 0.004) complications than the SA group. PreRT + S prevent recurrence in patients with WDLPS and low-grade DDLPS but is associated with increased complications, resulting in similar OS compared to SA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.